ロード中...
Spotlight on ixazomib: potential in the treatment of multiple myeloma
Despite the significant therapeutic advances achieved with proteasome inhibitors (PIs) such as bortezomib and carfilzomib in prolonging the survival of patients with multiple myeloma, the development of drug resistance, peripheral neuropathy, and pharmacokinetic limitations continue to pose major ch...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4714737/ https://ncbi.nlm.nih.gov/pubmed/26811670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S93602 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|